- Home
- Publications
- Publication Search
- Publication Details
Title
Pacritinib to treat myelofibrosis patients with thrombocytopenia
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2018-07-13
DOI
10.1080/17474086.2018.1500456
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study
- (2018) J. Mascarenhas et al. ANNALS OF HEMATOLOGY
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
- (2017) F Passamonti et al. LEUKEMIA
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis.
- (2017) H. J. Deeg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
- (2016) Guido Lancman et al. Expert Review of Hematology
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
- (2013) J. Mascarenhas et al. BLOOD
- Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
- (2013) Garrett W. Rhyasen et al. CANCER CELL
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies
- (2012) B Luo et al. ONCOGENE
- Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
- (2011) Anthony D. William et al. JOURNAL OF MEDICINAL CHEMISTRY
- SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
- (2011) S Hart et al. LEUKEMIA
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More